– USA, CA – Kalytera Therapeutics, Inc. (TSX: KALY | OTC: KALTF) is pleased to announce that Robert Farrell, J.D., has been appointed as the Company’s Chief Executive Officer. Mr. Farrell previously held the position of Interim CEO.
Mr. Pini Ben-Elazar, who served as a member of the Company’s Board of Directors since March 2017, has submitted his resignation from the Board of Directors, and the Company has accepted the resignation of Mr. David Bassa, who served as the COO.
“I would like to thank Mr. Ben-Elazar and Mr. Bassa for their contributions to Kalytera, including their guidance and advice regarding the Company’s GVHD program,” said Mr. Farrell. “We are now on track to advance our GVHD Program into a Phase 2 study that we anticipate can be completed in approximately eight months, at which time we will be positioned to initiate the pivotal Phase 3 study required for FDA approval.”
About Bob Farrell
Mr. Farrell has more than 25 years of experience in the pharmaceutical, biotechnology, and medical device sectors. Before joining Kalytera, Mr. Farrell worked as an executive officer with the Institute for One World Health, an affiliate of the Bill and Melinda Gates Foundation. Mr. Farrell has held senior positions with publicly listed companies in the pharmaceutical and biotechnology industries, including Titan Pharmaceuticals, where he served as President and CEO from 2008 to 2010, and as CFO from 1996 to 2008.
Mr. Farrell received a law degree (J.D.) from the University of California, and his undergraduate degree (B.A.) from the University of Notre Dame.
About Kalytera Therapeutics
Kalytera Therapeutics, Inc. is pioneering the development of the next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs. Kalytera is focused first on developing a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is a remarkable compound that has shown activity against several pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera is developing innovative CBD formulations and prodrugs to overcome these limitations and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, to limit future competition.
For more information: https://www.kalytera.co
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
